Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303108 · ClinicalTrials.gov registry record · Phase 2
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
A Phase 2 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT00303108: Completed Phase 2 study, sponsored by US Oncology Research.
NCT00303108 is a Phase 2 study that has completed, run by US Oncology Research. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00303108, a Phase 2 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
Primary Outcome
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR.
Interventions
- DRUG Carboplatin
- DRUG trastuzumab
- DRUG Pegylated liposomal doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2005-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT00303108 record still lists
NCT00303108 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00303108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00303108 about?
NCT00303108 is a clinical study titled "Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer". The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
What is the current status of trial NCT00303108?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2005-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00303108?
The interventions under investigation include: Carboplatin (DRUG), trastuzumab (DRUG), Pegylated liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00303108?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00303108's enrollment target sits among peer trials
136 527th of 2000 higher than 1,469 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia